We previously identified in NSCLC a subset of CD133+ lung cancer stem cells (CSCs), co-expressing CXCR4, endowed with stemness features and characterized by resistance to cisplatin and superior ability to seed distant site and initiate metastatic process (11–13). The gene discussed is CXCR4; the disease is lung cancer.